Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AAVenger platform has demonstrated transduction and long-term expression in lung tissue without impact on other tissue types in disease-relevant animal models. The platform can be applied to treat cystic fibrosis, interstitial lung disease, pulmonary fib...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 15, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
